(VIANEWS) – InterDigital (IDCC), Banco Latinoamericano de Comercio Exterior, S.A. (BLX), Amphastar Pharmaceuticals (AMPH) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. InterDigital (IDCC)
26.7% sales growth and 42.79% return on equity
InterDigital, Inc. operates as a global research and development company with focus primarily on wireless, visual, and related technologies. It designs and develops technologies that enable connected in a range of communications and entertainment products and services. It licenses or intend to license its innovations to companies providing products and services, including wireless communications, consumer electronics, personal computer, and automotive, as well as cloud-based services, such as video streaming. It designs and develops a range of innovations for use in digital cellular and wireless products and networks, including 2G, 3G, 4G, 5G, and IEEE 802-related products and networks. The company also develops cellular technologies, such as technologies related to CDMA, TDMA, OFDM/OFDMA, and MIMO for use in 2G, 3G, 4G, and 5G wireless networks, as well as mobile terminal devices; and 3GPP technology portfolio in 5G, 5G, advanced and 6G, as well as technologies for automobiles, wearables, smart homes, drones, and other connected consumer electronic products. In addition, it provides video coding and transmission technologies; and engages in the research and development of artificial intelligence. Further, the company's patented technologies are used in various products that include smartphones, tablets, consumer electronics, and base stations; televisions, laptops, gaming consoles, set-top boxes, streaming devices, and connected automobiles. InterDigital, Inc. was incorporated in 1972 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, InterDigital has a trailing twelve months EPS of $9.96.
PE Ratio
InterDigital has a trailing twelve months price to earnings ratio of 13.56. Meaning, the purchaser of the share is investing $13.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.79%.
2. Banco Latinoamericano de Comercio Exterior, S.A. (BLX)
22.7% sales growth and 16.19% return on equity
Banco Latinoamericano de Comercio Exterior, S.A., a multinational bank, primarily engages in the financing of foreign trade in Latin America and the Caribbean. The company operates through two segments, Commercial and Treasury. It offers short and medium-term bilateral, structured and syndicated credits, and loan commitments; financial guarantee contracts, such as issued and confirmed letters of credit, and stand-by letters of credit; and guarantees covering commercial risk and other assets, as well as co-financing arrangements, underwriting of syndicated credit facilities, structured trade financing in the form of factoring and vendor financing, and financial leasing. The company also provides treasury solutions, which include term deposits and private placements. It primarily serves financial institutions, corporations, and sovereigns and state-owned entities. The company was formerly known as Banco Latinoamericano de Exportaciones, S.A. and changed its name to Banco Latinoamericano de Comercio Exterior, S.A. in June 2009. Banco Latinoamericano de Comercio Exterior, S.A. was founded in 1977 and is headquartered in Panama City, the Republic of Panama.
Earnings Per Share
As for profitability, Banco Latinoamericano de Comercio Exterior, S.A. has a trailing twelve months EPS of $5.28.
PE Ratio
Banco Latinoamericano de Comercio Exterior, S.A. has a trailing twelve months price to earnings ratio of 6.08. Meaning, the purchaser of the share is investing $6.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.19%.
Sales Growth
Banco Latinoamericano de Comercio Exterior, S.A.’s sales growth is 46.3% for the current quarter and 22.7% for the next.
Volume
Today’s last reported volume for Banco Latinoamericano de Comercio Exterior, S.A. is 109200 which is 20.55% below its average volume of 137447.
Revenue Growth
Year-on-year quarterly revenue growth grew by 29.7%, now sitting on 271.04M for the twelve trailing months.
Yearly Top and Bottom Value
Banco Latinoamericano de Comercio Exterior, S.A.’s stock is valued at $32.11 at 20:22 EST, under its 52-week high of $34.45 and way above its 52-week low of $20.02.
3. Amphastar Pharmaceuticals (AMPH)
10.5% sales growth and 25.57% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $3.15.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 14.89. Meaning, the purchaser of the share is investing $14.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.57%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 12.2% and positive 12.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.2%, now sitting on 712.89M for the twelve trailing months.
4. Great Lakes Dredge & Dock Corporation (GLDD)
8.5% sales growth and 11.21% return on equity
Great Lakes Dredge & Dock Corporation provides dredging services in the United States. The company engages in capital dredging that consists of port expansion projects; coastal restoration and land reclamations; trench digging for pipelines, tunnels, and cables; and other dredging related to the construction of breakwaters, jetties, canals, and other marine structures. It is also involved in coastal protection projects that comprises of moving sand from the ocean floor to shoreline locations where erosion threatens shoreline assets; maintenance dredging, which consists of the re-dredging of previously deepened waterways and harbors to remove silt, sand, and other accumulated sediments; land reclamations, channel deepening, and port infrastructure development; and lake and river dredging, inland levee and construction dredging, environmental restoration and habitat improvement, and other marine construction projects. The company serves federal, state, and local governments; foreign governments; and domestic and foreign private concerns, such as utilities, oil, and other energy companies. It operates a fleet of 18 dredges, 17 material transportation barges, 1 drillboat, and various other support vessels. The company was formerly known as Lydon & Drews Partnership and changed its name to Great Lakes Dredge & Dock Corporation in 1905. Great Lakes Dredge & Dock Corporation was founded in 1890 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Great Lakes Dredge & Dock Corporation has a trailing twelve months EPS of $0.65.
PE Ratio
Great Lakes Dredge & Dock Corporation has a trailing twelve months price to earnings ratio of 18. Meaning, the purchaser of the share is investing $18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.21%.
Volume
Today’s last reported volume for Great Lakes Dredge & Dock Corporation is 499110 which is 2.4% below its average volume of 511432.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.2%, now sitting on 667.66M for the twelve trailing months.
Sales Growth
Great Lakes Dredge & Dock Corporation’s sales growth is 57.1% for the ongoing quarter and 8.5% for the next.
Moving Average
Great Lakes Dredge & Dock Corporation’s worth is way above its 50-day moving average of $9.60 and way above its 200-day moving average of $8.69.
5. DexCom (DXCM)
6.2% sales growth and 29.41% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $1.3.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 104.72. Meaning, the purchaser of the share is investing $104.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.41%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.3%, now sitting on 3.93B for the twelve trailing months.
Moving Average
DexCom’s worth is way higher than its 50-day moving average of $70.08 and way higher than its 200-day moving average of $110.68.
